The firm has a market capitalization of $1.98 billion, a PE ratio of 139.16 and a beta of 0.76. A final decision is expected by November 2023.25malx trulieve cannabis Shares of PCRX stock opened at $43.14 on Friday. The FDA accepts Pacira's (PCRX) sNDA filing, which seeks to expand the label of its pain drug Exparel to include both sciatic and femoral nerve blocks. PCRX : 42.89 (-0.58%) Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review Zacks - Thu Mar 30, 7:42AM CDT. Shares of Pacira (PCRX) have gained 12.6% over the past four weeks to close the last trading session at $46.60, but there could still be a solid upside left in the stock if short-term price. That is, how much change in market value, from how. The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.In PCRX's case, the question is, what change in market valuation is the firm generating from the investments it makes on an incremental basis.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |